Are the Norwegian health research investments in line with the disease burden? by Kinge, Jonas Minet et al.
Kinge et al. Health Research Policy and Systems 2014, 12:64
http://www.health-policy-systems.com/content/12/1/64RESEARCH Open AccessAre the Norwegian health research investments
in line with the disease burden?
Jonas Minet Kinge1*, Ingrid Roxrud2, Stein Emil Vollset1,3, Vegard Skirbekk1,4 and John-Arne Røttingen1,5Abstract
Background: The relationship between research funding across therapeutic areas and the burden of disease in
Norway has not been investigated. Further, few studies have looked at the association between national research
investments and the global disease burden. The aim of the present study was to analyze the correlation between a
significant part of Norwegian investment in health research and the burden of disease across therapeutic areas,
using both Norwegian and global burden of disease estimates.
Methods: We used research investment records for 2012 from the Research Council of Norway, and the investment
records distributed through liaison committees between regional health authorities and universities. Both were
classified by the Health Research Classification System (HRCS). Furthermore, we used the years of life lost and
Disability Adjusted Life Years (DALYs) for Norway and globally from the Global Burden of Disease 2010 project. We
created a matrix to match the expenditures by HRCS with the values from the Global Burden of Disease project.
Results: Disease-specific research funding increased with the Norwegian burden of disease measured as years of
life lost (correlation coefficient = 0.73). Similar findings were done when the Norwegian disease burden was
measured as DALYs (correlation coefficient = 0.62). The correlation between research funding and the global disease
burden was low both when years of life lost (correlation coefficient = 0.11) and DALYs (correlation coefficient = 0.12)
were used. Generally, when the disease burden was relatively high in Norway compared with the rest of the world,
research investments were also high.
Conclusions: Across therapeutic areas, the Norwegian research investments appeared aligned with the Norwegian
disease burden. The correlation between the Norwegian research investments and the global disease burden was
much lower.
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In the US in 1997 the National Institute of Health’s
working group on priority setting recommended using
public health needs as a criterion for research [1]. Simi-
lar recommendations have later been made in other
countries [2], which has motivated research to assess the
correlation between research funding and measures of
disease burden. Some of these studies, which have been
conducted in the US, the UK, and Australia, reveal high
correlations between research funding and measures of
disease burden [1,3-7]. However, other studies dispute
this [2,6,8,9], and cancer, in particular, appears to attract* Correspondence: jonas.minet.kinge@fhi.no
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unless otherwise stated.more funds relative to disease burden compared with
other diseases [2,5,7,9]. Some of the literature in this
field has examined different cancers with the general
finding that breast cancer attracts more funding relative
to disease burden than other types of cancer [1,3,6,8].
While the association between research funding and
burden of disease has been investigated in several coun-
tries, little attention has been paid to national research
investments and global disease burden. Such consider-
ations are important given recent calls for new strategies
for incorporating a global perspective into investments in
health research [10-12]. Health threats, as a result of
globalization, are becoming increasingly transnational and
social determinants of health at the national level are influ-
enced by global markets, migrations, and communication.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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needed. Furthermore, it can be argued that Norway, as a
rich country, has a special responsibility to conduct
research that reflects the health needs of developing
countries [13].
It has been suggested that health need is a key criter-
ion for deciding the allocation of resources for both
treatment and research [14,15]. However, health need
alone is not a sufficient criterion to determine research
priority, i.e., twice the health need does not justify twice
the investment in research. Such a decision must also
depend on the opportunity for progress in the area.
Without this consideration, less overall scientific pro-
gress in the field of health research would be accom-
plished, which would lead to less of a reduction in the
burden of disease than what could have been achieved
otherwise. In addition, there are a range of other criteria,
such as feasibility of the intervention, equity, and cost-
effectiveness, which must be included in a comprehen-
sive analysis to ensure that important considerations are
not overlooked. Hence, this is not a prioritization ana-
lysis, but rather a contribution to the debate on global
research funding.
The aim of the following analysis was to assess the
correlation between Norwegian research investments
and both the Norwegian and global burden of disease.
This was possible as both the Research Council of
Norway and the Regional Health Authorities have adopted
the International Health Research Classification System
(HRCS) to classify part of their efforts in health research
[16]. As a measure of Norwegian and global morbidity/
mortality, we used data from the International Global
Burden of Disease (GBD) 2010 project [17,18].
Data and methods
Research funding
Research in health and medical sciences performed by
public institutions in Norway is financed through differ-
ent channels, including the Ministry of Health and Care
Services, the Ministry of Education and Research, the
Research Council of Norway (RCN), the Regional Health
Authorities (RHA), charities, international sources, and
private companies [19]. Charities, international sources,
and private companies, however, were only responsible
for 12% of the total investments in public sector health
research in 2011; thus, 88% was publicly funded [20]. In
comparison with other high income nations, Norway has
a low involvement of the private sector in health re-
search [21].
We used portfolio data from the RCN [22] and RHAs
in 2012 to calculate research activity and investments.
Resource allocation was calculated based on the financial
investments in each of the projects in 2012. The RCN
has used the HRCS since 2011 and we included, fromthe RCN, investments related to the target area “Better
health and health care”. This amounted to NOK 783 mil-
lion (EUR 104 million), which was approximately 85% of
the RCN’s overall investments in the health field in 2012.
The RHAs have, since 2009, used HRCS to classify a
part of their projects. Hence, we could include approxi-
mately 29% (NOK 810 million, EUR 107 million) of the
RHA’s total expenditures (NOK 2.8 billion, EUR 371 mil-
lion) on research in 2012 [23]. We included the part of
their portfolios which was funded through liaison com-
mittees between the RHAs and the universities. Most of
these funds are earmarked research allocations from the
Ministry of Health and Care Services to the specialist
health care services. However, some are also basic fund-
ing from block grants to a broadly defined type of activ-
ity, including patient treatment, education, and research.
The part that is not classified by HRCS (NOK 2 billion,
EUR 264 million), and thus not included in our analysis,
consists mostly of block grants to broadly defined activ-
ities. It is not known if the HRCS profiles we observe
are representative of the overall research effort in the
RHAs [24].
In total, we include an amount of roughly NOK 1.6
billion (EUR 211 million) in research funding. The total
research investments in the public sector in the field of
medicine and health have not been estimated for 2012.
However, in 2011 this was NOK 6.2 billion (EUR 822
million) [20].
Measures of burden of disease
Several health-based burden measures have been pro-
posed (e.g., disability-adjusted life years (DALYs), quality-
adjusted life years, years of life lost (YLLs), and mortality),
which have different characteristics. In the following study,
we apply YLLs and DALYs, for Norway and globally, from
the GBD 2010 project [17,18]. GBD 2010 is an inter-
national project based at the Institute for Health Metrics
and Evaluation at the University of Washington. The aim
of the project is to provide a comparative overview of
population health and mortality as well as associated risk
factors. The results are stratified by age, gender, region,
and country. YLL measures loss of life due to premature
mortality and is calculated by subtracting the age at death
from the life expectancy for a person at that age. The use
of DALYs was initiated by the World Bank and WHO as
an overall measure of disease burden [25]. DALYs equal
the sum of YLLs and years lived with disability. Hence,
this measure incorporates loss of life due to nonfatal
health conditions with one DALY equal to the loss of one
year of healthy life.
The disease groups used in the HRCS and GBD cat-
egories are not directly comparable. Hence, we created
our own disease groups, which are displayed (Additional
file 1). An important weakness is that we could not match
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vance” with the disease-specific categories of the GBD.
These accounted for 30% of the RCN’s investments and
13% of the RHAs’ investments, thus constituting 22% of
the total investments in the analysis.
To illustrate the association between research invest-
ments and disease burden, we used scatter plots supple-
mented with linear trends. We also calculated correlation
coefficients (Pearson’s) for each association.
Results
The share of the total research investment across the
disease categories ranged from 19.4% in cancer to 0.5%
in injuries (Table 1). The disease category responsible
for most YLLs in Norway was cancer, followed by car-
diovascular disease. Musculoskeletal disorders, mental
health, and cancer caused most DALYs in Norway. Infec-
tions were most important both in terms of YLLs and
DALYs at the global level. Cardiovascular disease was
the second most important reason for both YLLs and
DALYs globally. The two last columns in Table 1 show
the relative ratio of Norwegian YLLs and DALYs com-
pared to global YLLs and DALYs. When the ratio is
above 1, the relative disease burden in Norway wasTable 1 Research investments in Norway in 2012 and the Nor
of life lost (YLLs) and disability-adjusted life years (DALYs)
Percentage share of total research investmen
Disease categories RCN, NOK
783 mill.
RHAs, NOK
810 mill.
RCN + RHAs,
NOK 1,593 mil
Musculoskeletal disorders 2.0% 4.3% 3.2%
Cancer 15.5% 23.1% 19.4%
Mental health 12.0% 12.8% 12.4%
Neurological disorders 10.3% 8.3% 9.3%
Metabolica 3.1% 4.1% 3.6%
Cardiovascular diseases 7.1% 13.0% 10.1%
Blood/urogenitalb 0.4% 2.55% 1.48%
Respiratory diseases 1.4% 0.9% 1.2%
Other nonc 0.8% 1.8% 1.3%
Oral and gastrointestinald 1.2% 2.0% 1.6%
Injuries 0.6% 0.4% 0.5%
Reproductive healthe 2.9% 3.5% 3.2%
Infection 7.6% 2.6% 5.0%
Correlation with the RCN investments
Correlation with the RHAs investments
Correlation with total investments (RCN + RHAs)
RCN, Research Council of Norway; RHA, Regional Health Authorities.
aAnd endocrine diseases.
bDiseases.
cCommunicable disorders.
dDiseases.
eAnd childbirth.higher than the global burden; conversely, ratios below 1
show that the relative disease burden globally was higher
than the Norwegian burden. In terms of YLLs, mental
health was 3.26 times as important for the total burden
of disease in Norway compared with globally. Musculo-
skeletal disorders were 2.6 times more important for the
total burden of disease in Norway compared with the
global burden, in terms of DALYs lost. On the other
hand, the burden from “reproductive health and child-
birth” and infectious diseases was much higher globally
in terms of both YLL and DALYs.
The correlation coefficients demonstrate a high correl-
ation between the total research investments included in
the analysis and associated disease burden, in terms of
YLLs and DALYs, in Norway (Table 1). The correlations
between the Norwegian disease burden and total re-
search investment were 0.73 for YLLs and 0.62 for
DALYs. The correlations between total research invest-
ments and the global disease burden were 0.11 for YLLs
and 0.12 for DALYs and were thus considerably weaker
than in the Norwegian case. The correlation between
Norwegian disease burden and investments was more
pronounced for the RHAs than for the RCN. In contrast,
at the global level, RCN investments correlated morewegian and global burden of disease, measured by years
ts Norway Global Rates
l.
% of
YLLs
% of
DALYs
% of
YLLs
% of
DALYs
Norway
YLLs/Global
YLLs
Norway
DALYs/Global
DALYs
0.6% 17.0% 0.2% 6.5% 2.00 2.6
32.8% 15.5% 10.7% 7.6% 1.78 2.0
3.8% 15.6% 0.5% 7.4% 3.26 2.1
5.2% 5.5% 1.8% 3.0% 2.78 1.8
2.6% 3.8% 2.0% 2.3% 0.86 1.6
27.9% 14.4% 15.9% 11.5% 1.27 1.3
1.6% 2.70% 1.9% 2.52% 1.06 1.1
5.3% 5.0% 4.0% 4.8% 0.89 1.1
1.5% 5.1% 2.4% 5.1% 0.43 1.0
3.1% 1.8% 3.4% 2.6% 0.81 0.7
10.0% 8.9% 13.5% 11.1% 0.59 0.8
1.6% 0.9% 12.2% 8.9% 0.05 0.1
4.2% 2.8% 29.6% 22.8% 0.33 0.1
0.59 0.51 0.19 0.24 0.63 0.41
0.80 0.67 0.05 0.04 0.57 0.53
0.73 0.62 0.11 0.12 0.61 0.49
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correlations between the RHAs’ investments and global
YLLs and DALYs were 0.05 and 0.04, respectively, i.e., al-
most non-existent.
The share of total research investments increased with
the relative ratios. This means that disorders with a par-
ticularly high disease burden in Norway, relative to the
global burden, attracted relatively more investments.
Conversely, it could mean that less was invested if the
disease burden was low in Norway relative to the rest of
the world. The positive correlation was higher for RHAs
(0.53) than for the RCN (0.41). This suggests that RHAs
are more focused on the Norwegian disease burden,
while the RCN has a more global profile.
Figure 1A–D displays the results from Table 1 with
scatter plots supplemented with linear regression lines
of the correlations. Figure 1A illustrates how the disease
category cancer, which accounted for a large proportion
of the YLLs, had the highest research investments. We
also see that cardiovascular diseases received less fund-
ing than both cancer and mental health. Figure 1B dem-
onstrates the consequence of taking both YLLs and
morbidity into account through DALYs. Compared with
YLLs, both cardiovascular disease and cancer are rela-
tively less important, while the magnitude of health loss
from both musculoskeletal diseases and mental health
increases significantly.
Figure 1C, D illustrates the results based on the global
YLLs and DALYs. Although the global trends were similar
to those of Norway, there are important differences of which
the most important is the increased burden from infectious
diseases. As Norway funds relatively little research on this
disease category, the correlations are weaker than that seen
when comparing with the Norwegian disease burden.
Figure 2 illustrates the relative Norwegian DALYs to
the global DALYs by disease category. This is mapped
against the total research investment included in the
analysis. As shown in the figure, the burden of musculo-
skeletal disorders has been especially high in Norway,
but the research investments have been relatively low.
The burden of diseases related to reproductive health
and childbirth as well as infectious diseases was very
small in Norway. With the exception of musculoskeletal
disorders, the RCN and RHAs invested more in diseases
in which the disease burden was high in Norway com-
pared with the rest of the world.
Discussion
We found that a significant part of research investment
in the health sector in Norway was highly correlated
with the disease burden in Norway, although with some
exceptions. This is important as it demonstrates that
investments in research largely follow the health needs
of the Norwegian population. The association betweeninvestments and the Norwegian disease burden was more
pronounced for the RHAs compared with the RCN. In
addition, we compared the Norwegian research invest-
ments with the global disease burden and found a positive
correlation. However, the association was less pronounced,
compared to the correlation between research investments
and the Norwegian disease burden. Finally, we illustrated,
using rates, that when the relative burden in Norway was
high, compared with the global burden, this disease
attracted more funds.
Different measures of disease burden can be used to
focus attention on different aspects of the disease [26,27].
YLLs measures have been found to better predict research
funding than mortality [1,27]. However, composite mea-
sures of disease burden that include both morbidity and
mortality, like DALYs, have been found to correlate more
with funding that YLLs [1,3]. We explored the use of two
measures of disease burden – YLLs and DALYs – and
found that the choice of either measure highly influenced
the ranking of disease categories. This disparity was pri-
marily manifested within non-fatal disorders. For example,
musculoskeletal and mental health disorders had a low
impact on disease burden when YLLs was used as the sole
criterion. However, when a composite measure of both
mortality and morbidity through DALYs was applied, the
burden from such disorders increased vastly. Such varia-
tions demonstrate how policy makers could be misled. By
using a single measure of burden, advocates interested in
promoting research on specific diseases could select mea-
sures that support their cause [1].
Norway, as a rich country, may have a special respon-
sibility to conduct research that reflects international
priorities and contribute knowledge that can support the
formulation of international health initiatives. Further,
the disease burden is a central criterion for setting prior-
ities in health research [14,15,28]. Our analysis shows
that musculoskeletal, neurological and mental health ill-
nesses were less important for the global burden com-
pared with the Norwegian burden. Conversely, infectious
diseases, reproductive health, and childbirth complica-
tions were pivotal globally, particularly in developing
countries. One might argue that these diseases deserve
particular attention as developing countries with low
GDP per capita have few resources available for health
research [15].
The findings suggest that the RCN investments are
more globally oriented than those of the RHAs. For ex-
ample, a larger share of the RCN’s investments was
invested in research on reproductive health and child-
birth complications, while the RHAs invested more in
musculoskeletal disorders. This is not surprising given
that the RHAs are responsible for covering all clinical
areas and invest in clinical research to a greater extent
than the RCN. In addition, hospitals indeed pay particular
A: YLL Norway B: DALYs Norway
C: YLL global D: DALYs global
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Figure 1 Scatter plots with research investments and the Norwegian YLLs (A), Norwegian DALYs (B), global YLLs (C), and global DALYs
(D). Note: the solid line lines depicted in each figure are the best-fit linear regression lines and the dashed lines show where funding match the
burden. BU, Blood and Urogenital disorders; Cardio, Cardiovascular diseases; ME, Metabolic and endocrine disorders; Musc, Musculoskeletal
disorders; Neuro, Neurological disorders; OG, Oral and Gastrointestinal disorders; ONCD, Other non-communicable diseases; Resp, Respiratory
diseases; RHC, reproductive health and childbirth.
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gram initiative in global health research.
In the portfolios we have analyzed, only a minor part
were the direct result of overall prioritization of certaindisease areas over others. It is therefore interesting that,
in a collection of portfolios which are distributed mainly
based on competition and without prioritized disease
areas, we see a positive correlation between financial
Figure 2 Scatter plot with the association between total research investments and rates (% Norway DALYs/global DALYs). The solid line
depicted is the best-fit linear regression line. Blood and Urogen, Blood and Urogenital; Reprod H & Childb, Reproductive health and childbirth.
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research system seems to sufficiently cover the range of
clinical activity and that there is room for high quality re-
search on most disease areas of importance.
We emphasize that the need criterion is not sufficient
for an efficient allocation of resources and cannot be
used exclusively for priority purposes as important parts
are lacking. The goal of activities to set priorities for
health research is to define an investment portfolio of
health research and development that will have the
greatest possible impact on the health of the majority of
the population [14]. To achieve this, other aspects must
be taken into the analysis such as the efficiency criterion
(the higher the priority, the higher the potential health
benefits) and the cost-effectiveness criterion (the higher
the priority, the greater the health benefit per invested
funds). To conduct a full prioritization analysis one
would need additional evidence on the costs of the dis-
orders and, importantly, the potential for scientific pro-
gress [1]. Further, there are other important goals and
drivers in Norwegian research policy such as the need to
stimulate a more research-intensive private sector, foster
high quality research and scientific excellence, and utilize
national advantages. Different criteria are applied depend-
ing on the context and research area.
Limitations
Our study has several limitations. First, our analysis is
limited by data availability as we have only been able to
classify parts of the total research investments in the
public sector in Norway. For example, we have not clas-
sified the basic funding to institutions such as univer-
sities and university hospitals, nor the funding stemmingfrom charities and private investments. Without taking
these types of funding into account, there is some uncer-
tainty regarding the generalizability of our therapeutic
specific classification as such institutions may prioritize
funding differently than those under consideration in
this study. Although private investments and charities
only accounted for 12% of the total investments in the
public sector in Norway in 2011, studies have found that
they invest differently than governmental agencies [2].
For example, in the UK, they found that charities invest
relatively more in cancer research [2].
Second, the burden of disease may be a result of in-
vestments in research, i.e., a low disease burden in some
categories might be a result of the Norwegian, and per-
haps above all the global, health research community in-
vestments into research on these diseases.
Third, our study hides the importance of general health
service research. There may be a burden from diseases
where effective prevention and treatment already exists,
yet resource constraints and local expertise limits
utilization and access. Hence, knowledge from research on
a specific clinical topic may be sufficient, but there is a
need for more knowledge about how health services can
be delivered and reach those with the greatest need.
Fourth, when using composite measures of disease
burden, which includes both the quality and quantity of
life lived, one must take into account that they reflect
the disability weight given to each health state. The use
of DALYs, as calculated by the GBD, to represent health
need is controversial for a number of reasons. DALYs have
conceptually been criticized for not reflecting health need.
The elicitation methods used to obtain the values for non-
fatal health conditions may have consequently caused low
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number of disabilities, such as blindness and deafness for
example, are not directly perceived as a health loss. As a
result, severe and chronic neck pain is ten times worse
than complete hearing loss [29] and this affects the rank-
ing of the health states. In addition, it is important to
recognize that the estimation of the true health loss from
a disability may vary by region. Wealthier regions may
have a different health loss from similar disorders com-
pared with poorer regions [8].
Conclusions
The aim of the current study was not to suggest how
much Norway should spend on particular disease groups,
but rather to inform decisions on the distribution of re-
search effort. The research investments included in the
analysis were highly correlated with the Norwegian disease
burden. However, the correlation with the global disease
burden was much lower. Generally, diseases that were
relatively important in Norway compared with the rest of
the world attracted more investments.
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